tamibarotene Publications
SELECT-AML-1: PHASE 2 RANDOMIZED TRIAL OF TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN ADULT PATIENTS WITH PREVIOUSLY UNTREATED WITH RARA OVEREXPRESSION, WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY
Borate U, et al. SOHO Annual Meeting. 2024
Abstract Number: AML-347
USE OF TAMIBAROTENE, A POTENT AND SELECTIVE RARΑ AGONIST, IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED AND REFRACTORY AML WITH RARA GENE OVEREXPRESSION
Stein E, et al. Leukemia & Lymphoma. AUGUST 2023
DOI: 10.1080/10428194.2023.2243356
TARGETING RARA OVEREXPRESSION WITH TAMIBAROTENE, A POTENT AND SELECTIVE RARΑ AGONIST, IS A NOVEL APPROACH IN AML
de Botton S, et al. Blood Advances. December 2022
doi: 10.1182/bloodadvances.2022008806
INITIAL RESULTS FROM SELECT-AML-1, A PHASE 2 STUDY OF TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN RARA-POSITIVE NEWLY DIAGNOSED AML PATIENTS INELIGIBLE FOR STANDARD INDUCTION CHEMOTHERAPY
Kambhampati S, et al. ASH Annual meeting. 2022
Abstract 1444
SELECTION OF RARA-POSITIVE NEWLY DIAGNOSED UNFIT AML PATIENTS WITH ELEVATED RARA GENE EXPRESSION ENRICHES FOR FEATURES ASSOCIATED WITH PRIMARY RESISTANCE TO VENETOCLAX AND CLINICAL RESPONSE TO SY‑1425, A POTENT AND SELECTIVE RARΑ AGONIST, PLUS AZACITIDINE
Fiore C, et al. ASH annual meeting. 2020
Abstract Number: 137323
SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, IN COMBINATION WITH AZACITIDINE DEMONSTRATES A HIGH COMPLETE RESPONSE RATE AND A RAPID ONSET OF RESPONSE IN RARA-POSITIVE NEWLY DIAGNOSED UNFIT ACUTE MYELOID LEUKEMIA
de Botton S, et al. ASH Annual Meeting. 2020
Abstract Number: 134600
INITIAL RESULTS FROM A BIOMARKER-DIRECTED PHASE 2 TRIAL OF SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, IN COMBINATION WITH AZACITIDINE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Stein E, et al. ASH Annual Meeting. 2020
Abstract Number: 134602
SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, IN COMBINATION WITH AZACITIDINE DEMONSTRATES HIGH RESPONSE RATES AND A RAPID ONSET OF CLINICAL RESPONSES IN RARA-POSITIVE NEWLY DIAGNOSED UNFIT AML
de Botton S, et al. ESH Conference on AML. 2019
Abstract Number: 16081
EARLY RESULTS FROM A BIOMARKER-DIRECTED PHASE 2 TRIAL OF SY-1425 IN COMBINATION WITH AZACITIDINE OR DARATUMUMAB IN NON-APL ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
Cook R, et al. ASH Annual Meeting. 2018
Abstract Number 2735
ANTITUMOR SYNERGY WITH SY-1425, A SELECTIVE RARα AGONIST, AND HYPOMETHYLATING AGENTS IN RETINOIC ACID RECEPTOR PATHWAY ACTIVATED MODELS OF ACUTE MYELOID LEUKEMIA
McKeown M, et al. Emmanuelle di Tomaso Haematologica. October 2018
DOI: 10.3324/haematol.2018.192807
EARLY RESULTS FROM A BIOMARKER-DIRECTED PHASE 2 TRIAL OF SY-1425 IN ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) DEMONSTRATE DHRS3 INDUCTION AND MYELOID DIFFERENTIATION FOLLOWING SY-1425 TREATMENT
Jurcic J, et al. ASH Annual Meeting. 2017.
Abstract Number: 2633
RARA PATHWAY ACTIVATION BIOMARKERS IN STUDY SY-1425-201 DEFINE A NEW SUBSET OF AML AND MDS PATIENTS AND CORRELATE WITH MYELOID DIFFERENTIATION FOLLOWING EX VIVO SY-1425 TREATMENT
Vigil C, et al. ESH Conference on AML. 2017
Abstract Number: 8882
TARGETING THE NONCODING GENOME: SUPERENHANCERS MEET THEIR KRYPTONITE
Wang E, Aifantis I. Cancer Discovery. 2017
DOI: 10.1158/2159-8290.CD-17-0860
PHARMACODYNAMIC AND PHARMACOKINETIC EVALUATION OF SY-1425 (TAMIBAROTENE) IN BIOMARKER-SELECTED ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Bixby D, et al. ESMO Congress. 2017
Abstract Number: 1032P
A BIOMARKER-DIRECTED PHASE 2 STUDY OF SY-1425, A SELECTIVE RETINOIC ACID RECEPTOR ALPHA AGONIST, IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
Cook R, et al. ASCO Annual Meeting. 2017
Abstract Number: TPS7071
SUPER-ENHANCER ANALYSIS DEFINES NOVEL EPIGENOMIC SUBTYPES OF NON-APL AML INCLUDING AN RARΑ DEPENDENCY TARGETABLE BY SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST
McKeown M. Et al.
Cancer Discovery
doi: 10.1158/2159-8290.CD-17-0399
2017
MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS
McKeown M, et al. EHA. 2017
Abstract Number: P188
SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, REPROGRAMS AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES, UNCOVERING PD MARKERS FOR CLINICAL STUDIES
McKeown M, et al. EHA. 2017
Abstract Number: E884
SY-1425 (TAMIBAROTENE), A POTENT SELECTIVE RARA AGONIST, INDUCES CHANGES IN THE TRANSCRIPTIONAL REGULATORY CIRCUIT OF AML CELLS LEADING TO DIFFERENTIATION
Fiore C, et al. AACR Annual Hematologic Malignancies Meeting. 2017
Poster Section: 6
EPIGENOMIC ANALYSIS OF PRIMARY BREAST CANCER TUMORS REVEALS NOVEL TUMOR CELL VULNERABILITIES AND THERAPEUTIC TARGETS
Guenther M, et al. IMPAKT Breast Cancer Conference. 2017
Abstract Number: 47P
SY-1425 (TAMIBAROTENE), A SELECTIVE RARA AGONIST, SHOWS SYNERGISTIC ANTI-TUMOR ACTIVITY WITH HYPOMETHYLATING AGENTS IN A BIOMARKER SELECTED SUBSET OF AML
McKeown M, et al. AACR Annual Meeting. 2017
Abstract Number: 3085
SY-1425, A SELECTIVE RARA AGONIST, INDUCES HIGH LEVELS OF CD38 EXPRESSION IN RARA-HIGH AML TUMORS CREATING A SUSCEPTIBILITY TO ANTI-CD38 THERAPEUTIC ANTIBODY TREATMENT
Austgen K, et al. AACR Annual Meeting. 2017
Poster Section: 26, Abstract Number: 2644
SUPER-ENHANCER LANDSCAPES REVEAL NOVEL EPIGENOMIC PATIENT SUBTYPES AND DRUGGABLE DEPENDENCIES IN HUMAN AML
Eaton M, et al. CSHL Systems Biology Meeting. 2017
A NOVEL SUBGROUP OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER MAY BENEFIT FROM SUPER-ENHANCER GUIDED PATIENT SELECTION FOR RETINOIC ACID RECEPTOR ALPHA AGONIST TREATMENT
McKeown M, et al. SABCS Annual Meeting. 2016
Program Number: P6-11-18
SY-1425 (TAMIBAROTENE) INDUCES PROFOUND TRANSCRIPTIONAL CHANGES IN AML TUMORS WITH HIGH RETINOIC ACID RECEPTOR ALPHA
Fiore C, et al. ASH Annual Meeting. 2016
Poster Section: 128, Abstract Number: 1523
CLINICAL PHARMACODYNAMIC MARKERS AND COMBINATIONS WITH SY-1425 (TAMIBAROTENE) IN A GENOMICALLY-DEFINE SUBSET OF NON-APL AML
McKeown M, et al. ASH Annual Meeting. 2016
Poster Section: 128, Abstract Number: 2898
SUPER-ENHANCER ANALYSIS DEFINES NOVEL AML AND MDS SUB-TYPES
Michael R. McKeown, Emily Lee, Chris Fiore, Matthew L. Eaton, Jeremy Lopez, Ryan Corces-Zimmerman, Ravindra Majeti, Kristin Stephens, Christian Fritz, and Eric Olson
EHA 21st Congress
Oral Presentation: Hall A3
Abstract Number: s807
June 12, 2016
SY-1425 IN GENOMICALLY DEFINED SUBSET OF AML AND MDS PATIENTS
Michael R. McKeown, Emily Lee, Chris Fiore, Matthew L. Eaton, Jeremy Lopez, Ryan Corces-Zimmerman, Ravindra Majeti, Christian Fritz, and Eric Olson
AACR Annual Meeting
Poster Section: 14
Abstract Number: 1187
2016